Murray D Esler

Author PubWeight™ 100.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010 14.40
2 Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2003 3.29
3 Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009 2.97
4 "Stress" and coronary heart disease: psychosocial risk factors. Med J Aust 2003 2.63
5 Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry 2008 2.43
6 Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012 2.21
7 Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension 2012 2.17
8 Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens 2007 2.09
9 Targeting the sympathetic nervous system: critical issues in patient selection, efficacy, and safety of renal denervation. Hypertension 2013 2.04
10 QT interval variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol 2008 1.85
11 Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 2011 1.80
12 Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2008 1.80
13 Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. Am J Clin Nutr 2008 1.75
14 Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009 1.67
15 Leptin-receptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic nerve activation in a Caucasian male population. Hypertens Res 2008 1.66
16 Persistence of muscle sympathetic nerve activity during vasovagal syncope. Eur Heart J 2010 1.56
17 Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens 2013 1.54
18 Sympathetic and cardiac baroreflex function in panic disorder. J Hypertens 2002 1.53
19 Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2012 1.52
20 Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adrenergic receptor genotype. J Am Coll Cardiol 2004 1.51
21 Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens 2005 1.44
22 Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure. Eur Heart J 2005 1.43
23 Oestrogen supplementation attenuates responses to psychological stress in elderly men rendered hypogonadal after treatment for prostate cancer. Clin Endocrinol (Oxf) 2002 1.40
24 Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005 1.39
25 Effects of weight loss on renal function in overweight Japanese men. Hypertens Res 2011 1.39
26 Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003 1.38
27 Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 2008 1.29
28 Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects. Diabetes 2012 1.25
29 Losartan increases bradykinin levels in hypertensive humans. Circulation 2005 1.25
30 Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation 2002 1.18
31 The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res 2010 1.12
32 Psychophysiological mechanisms in panic disorder: a correlative analysis of noradrenaline spillover, neuronal noradrenaline reuptake, power spectral analysis of heart rate variability, and psychological variables. Psychosom Med 2006 1.10
33 Baroreflex sensitivity: a reliable predictor of response to renal denervation? J Am Coll Cardiol 2014 1.09
34 Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol 2012 1.08
35 Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res 2007 1.08
36 International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013 1.05
37 Single-unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover. J Physiol 2011 1.03
38 Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes 2009 1.02
39 Raised sympathetic nerve activity in heart failure and central sleep apnea is due to heart failure severity. Circulation 2003 1.02
40 Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol 2013 1.01
41 Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 2010 0.98
42 Jugular venous overflow of noradrenaline from the brain: a neurochemical indicator of cerebrovascular sympathetic nerve activity in humans. J Physiol 2009 0.97
43 Autonomic control of the aging heart. Neuromolecular Med 2008 0.96
44 Postural syncope: mechanisms and management. Med J Aust 2007 0.95
45 The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab 2010 0.95
46 Short-term heart rate variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol 2009 0.94
47 Renal denervation and hypertension. Am J Hypertens 2011 0.93
48 European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. J Hypertens 2009 0.91
49 Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol 2012 0.91
50 Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circulation 2002 0.89
51 Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. Diabetes 2009 0.87
52 Chronic atrial fibrillation does not influence the magnitude of sympathetic overactivity in patients with heart failure. Eur Heart J 2003 0.85
53 Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep 2012 0.84
54 Baseline sympathetic nervous system activity predicts dietary weight loss in obese metabolic syndrome subjects. J Clin Endocrinol Metab 2011 0.84
55 Renal denervation: current implications and future perspectives. Clin Sci (Lond) 2014 0.84
56 Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 2004 0.81
57 Cardiac ablation and renal denervation systems have distinct purposes and different technical requirements. JACC Cardiovasc Interv 2013 0.80
58 Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension 2003 0.80
59 Change in sympathetic nerve firing pattern associated with dietary weight loss in the metabolic syndrome. Front Physiol 2011 0.80
60 Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation. EuroIntervention 2013 0.79
61 Recent advances in the treatment of hypertension. Expert Rev Cardiovasc Ther 2011 0.79
62 Effects of renal denervation on insulin resistance. Expert Rev Cardiovasc Ther 2012 0.79
63 New therapeutic approaches to resistant hypertension. Curr Hypertens Rep 2010 0.78
64 Health-related quality of life and blood pressure 12 months after renal denervation. J Hypertens 2015 0.78
65 Letter by Kaye and Esler regarding article "extracardiac progenitor cells repopulate most major cell types in the transplanted human heart". Circulation 2006 0.77
66 The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia. Obesity (Silver Spring) 2013 0.76
67 Atrial fibrillation is associated with decreased cardiac sympathetic response to isometric exercise in CHF in comparison to sinus rhythm. Pacing Clin Electrophysiol 2008 0.75
68 Letter by Schlaich et al regarding article, "Relationship between central sympathetic drive and magnetic resonance imaging determined left ventricular mass in essential hypertension". Circulation 2007 0.75
69 Response to quality of life after renal denervation. Hypertension 2013 0.75
70 Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007 0.75
71 Re: Cardiac denervation does/does not play a major role in exercise limitation after heart transplantation. J Appl Physiol (1985) 2008 0.75
72 Acute electrophysiologic effects of intravenous amiodarone are independent of a sympatholytic action in humans. J Cardiovasc Pharmacol 2003 0.75
73 Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. Int J Cardiol 2011 0.75
74 Divergent effects of ANP and BNP in acute heart failure: evidence for a putative BNP-selective receptor? J Hypertens 2002 0.75